Analysis on correlation between antinuclear antibodies and the efficacy of infliximab in Crohn′s disease patients
10.3760/cma.j.cn101480-20231128-00073
- VernacularTitle:英夫利西单克隆抗体治疗克罗恩病疗效与抗核抗体的相关性分析
- Author:
Songting WU
1
;
Dandan ZHU
1
;
Pingnan ZHANG
1
;
Na LI
1
;
Lei WANG
1
;
Xiaoqi ZHANG
1
;
Chenggong YU
1
Author Information
1. 南京大学医学院附属鼓楼医院消化科，南京 210008
- Publication Type:Journal Article
- Keywords:
Crohn′s disease;
Infliximab;
Antinuclear antibody;
Clinical response;
Adverse events;
Risk factors
- From:
Chinese Journal of Inflammatory Bowel Diseases
2024;08(3):217-222
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the correlation of antinuclear antibody (ANA) with clinical response to infliximab (IFX) in patients with Crohn′s disease (CD) .Methods:Patients who were diagnosed as CD and treated with IFX in Nanjing Drum Tower Hospital from January 2018 to September 2021 were retrospectively studied. The correlation analysis was used to explore the correlation between ANA and clinical response. These patients were divided into two groups according to the ANA titer after 25 weeks of IFX treatment. The differences in clinical data between the two groups were assessed by univariate analysis. The variables with P<0.15 in univariate analysis and having clinical significance were further analyzed by multivariate Logistic regression to determine the independent risk factors of the induction of ANA. Results:A total of 82 patients with CD were included. Forty-one (50.0%) patients were set as positive group, and 41 (50.0%) patients were set as negative group. In terms of clinical response, the clinical response rates of two groups were 68.3% and 41.5%, and the difference was significant (χ 2 = 5.959, P = 0.015) . Positive group was divided into 1∶100 subgroup ( n = 17) , 1∶320 subgroup ( n = 11) and ≥1∶1000 subgroup ( n = 13) . The clinical response rates of three groups were 41.2%, 45.5% and 7.7% respectively, and the difference was not statistically significant (χ 2 = 5.334, P = 0.084) . The incidences of adverse events in the two groups were 17.1% and 7.3%, and the difference was not significant (χ 2 = 1.822, P = 0.177) . Univariate analysis showed that the difference of total protein (TP) before IFX treatment between the positive group and negative group was statistically significant ( P<0.05) . Multivariate logistic regression analysis showed that age ( OR = 1.060, 95% CI: 1.015 ~ 1.107, P = 0.008) and the baseline TP ( OR = 1.110, 95% CI: 1.023 ~ 1.205, P = 0.012) were the independent risk factors for the induction of ANA. Conclusions:The formation of ANA may affect the clinical response of IFX, so the ANA titer should be monitored regularly during the IFX therapy. In addition, age and baseline TP are related to the formation of ANA.
